MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
"Triple Helix" Innovation Model
3. Triple Helix _ Dynamics
5. Intermediary (Investors, Funders, Regulator) Rankings, Ratings & Reviews
Intermediaries: Geographic Info
*Bioscience Regional Clusters & HotSpots
*Industry: Massachusetts
Replimune Group, Inc. (NASDAQ: REPL)*
Organization & Developments: Replimune
Parents
Replimune Group, Inc. (NASDAQ: REPL)*
Children
*Biotechnology company, develops oncolytic immune-gene therapies to treat cancer.
2019: Replimune Group: Updates To Thesis, Data Approaching In Q4_seekingalpha.com
2019: Replimune: Unchanged Since IPO, Run-Up Expected Into Clinical Data_seekingalpha.com
2020: Replimune: Interesting Developer Of Oncolytic Immunotherapies
2021: Replimune: Oncolytic Immunotherapy Pioneer Gaining Momentum In The Clinic
2022: Revisiting Replimun_ seekingalpha.com
2023: Replimune: Skepticism Is Priced In Ahead Of Long-Awaited CERPASS Data (Rating Upgrade)_ seekingalpha.com
2024: Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug
2024: Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch
2024: Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cance_ seekingalpha.com
2024: Replimune's RP1 Shows 33.6% Response Rate in Melanoma Trial, Marks Breakthrough
2024: Replimune's SWOT analysis: stock outlook as RP1 nears key milestones
2025: FDA rejects Replimune skin cancer therapy
2025: Replimune Group: Analysts Are More Optimistic Than The Market
2025: Replimune: A Misunderstood Contender In Oncolytics
2025: Replimune's shares crater as FDA rejects melanoma drug
2025: Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock
2026: FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients_20260501_2
2026: How a group of biotechs ran a covert campaign to push out the FDA commissioner
2026: Replimune: Second CRL May Have Sealed RP1's Fate - It's Hard To See Positives
Jumps
*Key People: Replimune
Finance & Acquisitions: Replimune